Biotech | October 18, 2021
U.S. FDA advisory committee recommends J&J booster dose
U.S. FDA to decide whether to authorize a booster dose in the coming days
U.S. FDA to decide whether to authorize a booster dose in the coming days
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
This opens up a huge market for the company’s Magnezis implants in India
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Subscribe To Our Newsletter & Stay Updated
